We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Brookdale Senior Living (BKD - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Brookdale Senior Living is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Brookdale Senior Living is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BKD's full-year earnings has moved 9% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, BKD has moved about 13.1% on a year-to-date basis. In comparison, Medical companies have returned an average of 2.9%. This means that Brookdale Senior Living is outperforming the sector as a whole this year.
Another stock in the Medical sector, Halozyme Therapeutics (HALO - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 27.4%.
The consensus estimate for Halozyme Therapeutics' current year EPS has increased 3.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Brookdale Senior Living belongs to the Medical - Nursing Homes industry, a group that includes 2 individual stocks and currently sits at #3 in the Zacks Industry Rank. Stocks in this group have lost about 3.3% so far this year, so BKD is performing better this group in terms of year-to-date returns.
Halozyme Therapeutics, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 510-stock industry is ranked #64. The industry has moved +6% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Brookdale Senior Living and Halozyme Therapeutics as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Brookdale Senior Living (BKD - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Brookdale Senior Living is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Brookdale Senior Living is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BKD's full-year earnings has moved 9% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, BKD has moved about 13.1% on a year-to-date basis. In comparison, Medical companies have returned an average of 2.9%. This means that Brookdale Senior Living is outperforming the sector as a whole this year.
Another stock in the Medical sector, Halozyme Therapeutics (HALO - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 27.4%.
The consensus estimate for Halozyme Therapeutics' current year EPS has increased 3.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Brookdale Senior Living belongs to the Medical - Nursing Homes industry, a group that includes 2 individual stocks and currently sits at #3 in the Zacks Industry Rank. Stocks in this group have lost about 3.3% so far this year, so BKD is performing better this group in terms of year-to-date returns.
Halozyme Therapeutics, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 510-stock industry is ranked #64. The industry has moved +6% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Brookdale Senior Living and Halozyme Therapeutics as they could maintain their solid performance.